CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
Authors:
- Rita TerenzianiRTRita Terenziani
- Maricla GalettiMGMaricla Galetti
- Silvia La MonicaSilvia La Monica
- Claudia FumarolaCFClaudia Fumarola
- Silvia ZoppiSZSilvia Zoppi
- Roberta AlfieriRoberta Alfieri
- Graziana DigiacomoGraziana Digiacomo
- Andrea CavazzoniACAndrea Cavazzoni
- Delia CavalloDCDelia Cavallo
- Massimo CorradiMassimo Corradi
- Marcello TiseoMarcello Tiseo
- Pier Giorgio PetroniniPPPier Giorgio Petronini
Open Access
Abstract
Background: The loss of the CDKN2A/ARF (cyclin-dependent kinase inhibitor 2A/alternative reading frame) gene is the most common alteration in malignant pleural mesothelioma (MPM), with an incidence of about 70%, thus representing a novel target for mesothelioma treatment. In the present study, we evaluated the antitumor potential of combining the standard chemotherapy regimen used for unresectable MPM with the CDK4/6 (cyclin-dependent kinase 4 or 6) inhibitor abemaciclib. Methods: Cell viability, cell death, senescence, and autophagy induction were evaluated in two MPM cell lines and in a primary MPM cell culture. Results: The simultaneous treatment of abemaciclib with cisplatin and pemetrexed showed a greater antiproliferative effect than chemotherapy alone, both in MPM cell lines and in primary cells. This combined treatment induced cellular senescence or autophagic cell death, depending on the cell type. More in detail, the induction of cellular senescence was related to the increased expression of p21, whereas autophagy induction was due to the impairment of the AKT/mTOR signaling. Notably, the effect of the combination was irreversible and no resumption in tumor cell proliferation was observed after drug withdrawal. Conclusion: Our results demonstrated the therapeutic potential of CDK4/6 inhibitors in combination with chemotherapy for the treatment of MPM and are consistent with the recent positive results in the MiST2 arm in abemaciclib-treated patients.Keywords
Funding Information
- Associazione Augusto per la vita (Novellara, RE, Italy) (0184/2018)
- Transfer Oil (Colorno, PR, Italy) (0184/2018)
- Fondazione Cariparma (0184/2018)
This publication has 45 references indexed in Scilit:
- Modification of the DNA Damage Response by Therapeutic CDK4/6 InhibitionJournal of Biological Chemistry, 2012
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapyCell Cycle, 2012
- Examination of the expanding pathways for the regulation of p21 expression and activityCellular Signalling, 2010
- Autophagic cell death induced by 5-FU in Bax or PUMA deficient human colon cancer cellCancer Letters, 2010
- Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell linesMolecular Cancer Therapeutics, 2008
- A mathematical approach to study combined effects of toxicants in vitro: Evaluation of the Bliss independence criterion and the Loewe additivity modelToxicology in Vitro, 2007
- Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosisCell Death & Differentiation, 2005
- Apoptotic and autophagic cell death induced by histone deacetylase inhibitorsProceedings of the National Academy of Sciences, 2004
- MDM2 Is a Negative Regulator of p21 , Independent of p53Journal of Biological Chemistry, 2004
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984